Webb11 apr. 2024 · It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the... WebbProQR is a clinical stage biotech company based in the Netherlands that discovers and develops unique RNA-based therapies for severe genetic disorders. ProQR Announces …
ProQR Therapeutics - Crunchbase Company Profile & Funding
Webb29 mars 2024 · (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology … Webb29 mars 2024 · Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event 03/29/2024 08:08am EDT ProQR today announced AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 as initial pipeline programs. maa worthington apartments
ProQR Announces Third Quarter 2024 Operating and ... - ProQR …
Webb29 mars 2024 · ProQR Therapeutics N.V. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported sales was EUR 4.04 million compared to EUR 1.35 million a year ago. Net loss was EUR 65.11 million compared to EUR 61.62 million a year ago. WebbProQR is a clinical stage biotech company based in the Netherlands that discovers and develops unique RNA-based therapies for severe genetic disorders. ProQR to Highlight a … Webb6 apr. 2024 · ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. About the company Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years Volatile share price over the past 3 months See All Risk Checks My Notes maa worthington resident login